Catalyst Pharmaceuticals saw its IBD SmartSelect Composite Rating rise to 96 Friday, up from 93 the day before.
The new score means the company is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria.
Catalyst Pharmaceuticals is not currently near a proper buy zone. See if the stock goes on to form a new chart pattern and offer a new buying opportunity.
Looking For The Best Stocks To Buy And Watch? Start Here
The stock has a 99 EPS Rating, meaning its recent quarterly and annual earnings growth is outpacing 99% of all stocks.
Its Accumulation/Distribution Rating of C- shows a roughly equal amount of buying and selling by institutional investors over the last 13 weeks.
In Q4, the company reported 32% earnings-per-share growth. Revenue growth climbed 28%, up from 25% in the prior quarter. The company has now posted accelerating growth in each of the last three reports.
Catalyst Pharmaceuticals earns the No. 2 rank among its peers in the Medical-Biomed/Biotech industry group. GeneDx Holdings is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
